Elahe Salehi, DNP, ANP-BC
Nurse Practitioner, Department of Breast Oncology
Director of Advanced Practice Nursing, Division of Women’s Cancers
Dana-Farber Cancer Institute
Boston, MA

Elahe Salehi, DNP, ANP-BC, is currently working as an oncology nurse practitioner for Department of Breast Oncology. Her research focuses on improving the experience and safety of receiving cancer-directed therapies, with a focus on reducing toxicity and improving quality of life. She has designed and implemented Scalp Cooling Best Practice Guidelines and Policies at DFCI and is the Principal Investigator of DFHCC trial 21-169 (Assessing the Impact of Scalp Cooling in Patients with Metastatic Breast Cancer).  Elahe Salehi began her nursing career in inpatient oncology, where she developed a passion for all oncology patients. She continued her career in the ambulatory oncology settings; for the last 12 years, her focus has been providing care to breast cancer patients from initial diagnosis through end-of-life care. She was honoured by one of her young breast cancer patients by inclusion in the 2017 Salute to Nurses in The Boston Globe. She is the recipient of the 2019 Dana-Farber President’s Award for Nursing Excellence, presented by the DFCI Nursing and Patient Care Services Department. Elahe Salehi received her Bachelor of Science in Nursing at Ryerson University in 2002, MSN-NP Adult Oncology at the Yale School of Nursing in 2006, and Doctor of Nursing Practice at MGH Institution of Health Professions in 2019. She is board certified as a nurse practitioner through the American Nurses Credentialing Center.

It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Planner/Faculty:
Jennifer A. McKenna, NP–has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty:
Elahe Salehi, DNP, ANP-BC–has no relevant financial relationships to disclose in relation to the content of this activity.

Peer Reviewer:
Lauren Olalde, RN–is on the speakers' bureau for Trodelvy.  

CEC Staff:
Bryan C. Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Jessica Hall–has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.